Atopic dermatitis epidemiology and unmet need in the United Kingdom

References

• Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130:1344–1354.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;92:44–47.
   Google Scholar
• Jungersted JM, Scheer H, Mempel M, et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy. 2010;65:911–918.
   PubMed Web of Science ®Google Scholar
• Ben-Gashir MA, Seed PT, Hay RJ. Predictors of atopic dermatitis severity over time. J Am Acad Dermatol. 2004;50:349–356.
   PubMed Web of Science ®Google Scholar
• Kay J, Gawkrodger DJ, Mortimer MJ, et al. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30:35–39.
   PubMed Web of Science ®Google Scholar
• Prescott-Clarke P, Primatesta P. The health survey for England 1996. London: The Stationery Office; 1998.
   Google Scholar
• Simpson CR, Newton J, Hippisley-Cox J, et al. Trends in the epidemiology and prescribing of medication for eczema in England. J R Soc Med. 2009;102:108–117.
   PubMed Web of Science ®Google Scholar
• Asher MI, Montefort S, Björkstén S, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733–743.
   PubMed Web of Science ®Google Scholar
• Deckers IA, McLean S, Linssen S, et al. Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies. PLoS One. 2012;7:e39803.
   PubMed Web of Science ®Google Scholar
• Pols DH, Wartna JB, Moed H, et al. Atopic dermatitis, asthma and allergic rhinitis in general practice and the open population: a systematic review. Scand J Prim Health Care. 2016;34:143–150.
   PubMed Web of Science ®Google Scholar
• Severity scoring of atopic dermatitis: The SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186:23–31.
   PubMed Web of Science ®Google Scholar
• Fennessy M, Coupland S, Popay J, et al. The epidemiology and experience of atopic eczema during childhood: a discussion paper on the implications of current knowledge for health care, public health policy and research. J Epidemiol Community Health. 2000;54:581–589.
   PubMed Web of Science ®Google Scholar
• Su JC, Kemp AS, Varigos GA, et al. Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997;76:159–162.
   PubMed Web of Science ®Google Scholar
• Benton EC, Kerr OA, Fisher A, et al. The changing face of dermatological practice: 25 years' experience. Br J Dermatol. 2008;159:413–418.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Rind D, Chapman R, et al. Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis. J Drugs Dermatol. 2018;17:750–756.
   PubMed Web of Science ®Google Scholar
• Zink A, Arents B, Fink-Wagner A, et al. Out-of-pocket costs for individuals with atopic eczema: a cross-sectional study in nine European countries. Acta Derm Venereol. 2019;99:263–267.
   PubMed Web of Science ®Google Scholar
• Daud LR, Garralda ME, David TJ. Psychosocial adjustment in preschool children with atopic eczema. Arch Dis Child. 1993;69:670–676.
   PubMed Web of Science ®Google Scholar
• Elliott BE, Luker K. The experiences of mothers caring for a child with severe atopic eczema. J Clin Nurs. 1997;6:241–247.
   PubMed Web of Science ®Google Scholar
• Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children? Br J Dermatol. 2001;144:514–522.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118:226–232.
   PubMed Web of Science ®Google Scholar
• Eckert L, Gupta S, Amand C, et al. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77:274–279.
   PubMed Web of Science ®Google Scholar
• Silverberg JI. Health care utilization, patient costs, and access to care in US adults with eczema: a population-based study. JAMA Dermatol. 2015;151:743–752.
   PubMed Web of Science ®Google Scholar
• Shum KW, Lawton S, Williams HC, et al. The British Association of Dermatologists audit of atopic eczema management in secondary care. Phase 3: audit of service outcome. Br J Dermatol. 2000;142:721–727.
   PubMed Web of Science ®Google Scholar
• Shum KW, Lawton S, Williams HC, et al. The British Association of Dermatologists audit of atopic eczema management in secondary care. Phase 1: audit of service structure. Br J Dermatol. 1999;141:430–437.
   PubMed Web of Science ®Google Scholar
• Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441–446.
   PubMed Web of Science ®Google Scholar
• Baurecht H, Irvine AD, Novak N, et al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol. 2007;120:1406–1412.
   PubMed Web of Science ®Google Scholar
• Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120:150–155.
   PubMed Web of Science ®Google Scholar
• Jarrett R, Salio M, Lloyd-Lavery A, et al. Filaggrin inhibits generation of CD1a neolipid antigens by house dust mite-derived phospholipase. Sci Transl Med. 2016;8:325ra18.
   PubMed Web of Science ®Google Scholar
• Lavker RM, Matoltsy AG. Formation of horny cells: the fate of cell organelles and differentiation products in ruminal epithelium. J Cell Biol. 1970;44:501–512.
   PubMedGoogle Scholar
• Denecker G, Hoste E, Gilbert B, et al. Caspase-14 protects against epidermal UVB photodamage and water loss. Nat Cell Biol. 2007;9:666–674.
   PubMed Web of Science ®Google Scholar
• Riethmuller C, McAleer MA, Koppes SA, et al. Filaggrin breakdown products determine corneocyte conformation in patients with atopic dermatitis. J Allergy Clin Immunol. 2015;136:1573–1580.
   PubMed Web of Science ®Google Scholar
• Jang H, Matsuda A, Jung K, et al. Skin pH is the master switch of kallikrein 5-mediated skin barrier destruction in a murine atopic dermatitis model. J Invest Dermatol. 2016;136:127–135.
   PubMed Web of Science ®Google Scholar
• Kezic S, O’Regan GM, Lutter R, et al. Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency. J Allergy Clin Immunol. 2012;129:1031–1039.e1.
   PubMed Web of Science ®Google Scholar
• Steinert PM, Marekov LN. The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope. J Biol Chem. 1995;270:17702–17711.
   PubMed Web of Science ®Google Scholar
• Kezic S, Kemperman PM, Koster ES, et al. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. J Invest Dermatol. 2008;128:2117–2119.
   PubMed Web of Science ®Google Scholar
• Bibel DJ, Aly R, Lahti L, et al. Microbial adherence to vulvar epithelial cells. J Med Microbiol. 1987;23:75–82.
   PubMed Web of Science ®Google Scholar
• Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22:850–859.
   PubMed Web of Science ®Google Scholar
• Nakatsuji T, Chen TH, Narala S, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med. 2017;9 pii: eaah4680. DOI:10.1126/scitranslmed.aah4680
   PubMed Web of Science ®Google Scholar
• Oh J, Conlan S, Polley EC, et al. Shifts in human skin and nares microbiota of healthy children and adults. Genome Med. 2012;4:77.
   PubMed Web of Science ®Google Scholar
• Winge MC, Hoppe T, Berne B, et al. Filaggrin genotype determines functional and molecular alterations in skin of patients with atopic dermatitis and ichthyosis vulgaris. PLoS One. 2011;6:e28254.
   PubMed Web of Science ®Google Scholar
• Vasilopoulos Y, Cork MJ, Teare D, et al. A nonsynonymous substitution of cystatin A, a cysteine protease inhibitor of house dust mite protease, leads to decreased mRNA stability and shows a significant association with atopic dermatitis. Allergy. 2007;62:514–519.
   PubMed Web of Science ®Google Scholar
• Vasilopoulos Y, Cork MJ, Murphy R, et al. Genetic association between an AACC insertion in the 3'UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J Invest Dermatol. 2004;123:62–66.
   PubMed Web of Science ®Google Scholar
• He JQ, Chan-Yeung M, Becker AB, et al. Genetic variants of the IL13 and IL4 genes and atopic diseases in at-risk children. Genes Immun. 2003;4:385–389.
   PubMed Web of Science ®Google Scholar
• Lesiak A, Kuna P, Zakrzewski M, et al. Combined occurrence of filaggrin mutations and IL-10 or IL-13 polymorphisms predisposes to atopic dermatitis. Exp Dermatol. 2011;20:491–495.
   PubMed Web of Science ®Google Scholar
• Namkung JH, Lee JE, Kim E, et al. Association of polymorphisms in genes encoding IL-4, IL-13 and their receptors with atopic dermatitis in a Korean population. Exp Dermatol. 2011;20:915–919.
   PubMed Web of Science ®Google Scholar
• Paternoster L, Standl M, Waage J, et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015;47:1449–1456.
   PubMed Web of Science ®Google Scholar
• Walley AJ, Chavanas S, Moffatt MF, et al. Gene polymorphism in Netherton and common atopic disease. Nat Genet. 2001;29:175–178.
   PubMed Web of Science ®Google Scholar
• Yousef GM, Scorilas A, Magklara A, et al. The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family – genomic characterization, mapping, tissue expression and hormonal regulation. Gene. 2000;254:119–128.
   PubMed Web of Science ®Google Scholar
• McNally NJ, Williams HC, Phillips DR, et al. Is there a geographical variation in eczema prevalence in the UK? Evidence from the 1958 British Birth Cohort Study. Br J Dermatol. 2000;142:712–720.
   PubMed Web of Science ®Google Scholar
• Schäfer T, Vieluf D, Behrendt H, et al. Atopic eczema and other manifestations of atopy: results of a study in East and West Germany. Allergy. 1996;51:532–539.
   PubMed Web of Science ®Google Scholar
• Arlian LG, Bernstein D, Bernstein IL, et al. Prevalence of dust mites in the homes of people with asthma living in eight different geographic areas of the United States. J Allergy Clin Immunol. 1992;90:292–300.
   PubMed Web of Science ®Google Scholar
• Molloy HF, LaMont-Gregory E, Idzikowski C, et al. Overheating in bed as an important factor in many common dermatoses. Int J Dermatol. 1993;32:668–672.
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117:411–417.
   PubMed Web of Science ®Google Scholar
• Comoy EE, Pestel J, Duez C, et al. The house dust mite allergen, Dermatophagoides pteronyssinus, promotes type 2 responses by modulating the balance between IL-4 and IFN-gamma. J Immunol. 1998;160:2456–2462.
   PubMed Web of Science ®Google Scholar
• Tan BB, Weald D, Strickland I, et al. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet. 1996;347:15–18.
   PubMed Web of Science ®Google Scholar
• Wan H, Winton HL, Soeller C, et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest. 1999;104:123–133.
   PubMed Web of Science ®Google Scholar
• McNally NJ, Williams HC, Phillips DR, et al. Atopic eczema and domestic water hardness. Lancet. 1998;352:527–531.
   PubMed Web of Science ®Google Scholar
• Danby SG, Brown K, Wigley AM, et al. The effect of water hardness on surfactant deposition following washing and subsequent skin irritation in atopic dermatitis patients and healthy controls. J Invest Dermatol. 2018;138:68–77.
   PubMed Web of Science ®Google Scholar
• White MI, Jenkinson DM, Lloyd DH. The effect of washing on the thickness of the stratum corneum in normal and atopic individuals. Br J Dermatol. 1987;116:525–530.
   PubMed Web of Science ®Google Scholar
• Kao JS, Fluhr JW, Man MQ, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol. 2003;120:456–464.
   PubMed Web of Science ®Google Scholar
• Sheu HM, Lee JY, Chai CY, et al. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol. 1997;136:884–890.
   PubMed Web of Science ®Google Scholar
• Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006;155:680–687.
   PubMed Web of Science ®Google Scholar
• Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol. 1974;90:525–530.
   PubMed Web of Science ®Google Scholar
• Brauweiler AM, Goleva E, Leung DYM. Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol. 2014;134:2114–2121.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Oscherwitz J, Cease KB, et al. Staphylococcus δ-toxin induces allergic skin disease by activating mast cells. Nature. 2013;503:397–401.
   PubMed Web of Science ®Google Scholar
• Novak N, Allam JP, Bieber T. Allergic hyperreactivity to microbial components: A trigger factor of “intrinsic” atopic dermatitis? J Allergy Clin Immunol. 2003;112:215–216.
   PubMed Web of Science ®Google Scholar
• Hirasawa Y, Takai T, Nakamura T, et al. Staphylococcus aureus extracellular protease causes epidermal barrier dysfunction. J Invest Dermatol. 2010;130:614–617.
   PubMed Web of Science ®Google Scholar
• Kita K, Sueyoshi N, Okino N, et al. Activation of bacterial ceramidase by anionic glycerophospholipids: possible involvement in ceramide hydrolysis on atopic skin by Pseudomonas ceramidase. Biochem J. 2002;362:619–626.
   PubMed Web of Science ®Google Scholar
• Miedzobrodzki J, Kaszycki P, Bialecka A, et al. Proteolytic activity of Staphylococcus aureus strains isolated from the colonized skin of patients with acute-phase atopic dermatitis. Eur J Clin Microbiol Infect Dis. 2002;21:269–276.
   PubMed Web of Science ®Google Scholar
• Ardern-Jones MR, Black AP, Bateman EA, et al. Bacterial superantigen facilitates epithelial presentation of allergen to T helper 2 cells. Proc Natl Acad Sci USA. 2007;104:5557–5562.
   PubMed Web of Science ®Google Scholar
• Nemoto-Hasebe I, Akiyama M, Nomura T, et al. Clinical severity correlates with impaired barrier in filaggrin-related eczema. J Invest Dermatol. 2009;129:682–689.
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol. 1994;30:535–546.
   PubMed Web of Science ®Google Scholar
• Wood LC, Elias PM, Calhoun C, et al. Barrier disruption stimulates interleukin-1 alpha expression and release from a pre-formed pool in murine epidermis. J Invest Dermatol. 1996;106:397–403.
   PubMed Web of Science ®Google Scholar
• Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001;15:985–995.
   PubMed Web of Science ®Google Scholar
• Salimi M, Barlow JL, Saunders SP, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013;210:2939–2950.
   PubMed Web of Science ®Google Scholar
• Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3:673–680.
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–490.
   PubMed Web of Science ®Google Scholar
• Halim TY, Hwang YY, Scanlon ST, et al. Group 2 innate lymphoid cells license dendritic cells to potentiate memory TH2 cell responses. Nat Immunol. 2016;17:57–64.
   PubMed Web of Science ®Google Scholar
• Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest. 1994;94:870–876.
   PubMed Web of Science ®Google Scholar
• Hamid Q, Naseer T, Minshall EM, et al. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol. 1996;98:225–231.
   PubMed Web of Science ®Google Scholar
• Bilsborough J, Leung DY, Maurer M, et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2006;117:418–425.
   PubMed Web of Science ®Google Scholar
• Ungar B, Garcet S, Gonzalez J, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137:603–613.
   PubMed Web of Science ®Google Scholar
• Suárez-Fariñas M, Tintle SJ, Shemer A, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011;127:954–964.
   PubMed Web of Science ®Google Scholar
• Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol. 2001;117:977–983.
   PubMed Web of Science ®Google Scholar
• Daines MO, Chen W, Tabata Y, et al. Allergen-dependent solubilization of IL-13 receptor α2 reveals a novel mechanism to regulate allergy. J Allergy Clin Immunol. 2007;119:375–383.
   PubMed Web of Science ®Google Scholar
• Herberth G, Heinrich J, Röder S, et al. Reduced IFN-gamma- and enhanced IL-4-producing CD4+ cord blood T cells are associated with a higher risk for atopic dermatitis during the first 2 yr of life. Pediatr Allergy Immunol. 2010;21:5–13.
   PubMed Web of Science ®Google Scholar
• Zheng T, Oh MH, Oh SY, et al. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol. 2009;129:742–751.
   PubMed Web of Science ®Google Scholar
• Mori A, Kaminuma O, Suko M, et al. Cellular and molecular mechanisms of IL-5 synthesis in atopic diseases: a study with allergen-specific human helper T cells. J Allergy Clin Immunol. 1997;100:S56–S64.
   PubMed Web of Science ®Google Scholar
• Grimstad O, Sawanobori Y, Vestergaard C, et al. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol. 2009;18:35–43.
   PubMed Web of Science ®Google Scholar
• Savinko T, Matikainen S, Saarialho-Kere U, et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol. 2012;132:1392–1400.
   PubMed Web of Science ®Google Scholar
• Wood N, Whitters MJ, Jacobson BA, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med. 2003;197:703–709.
   PubMed Web of Science ®Google Scholar
• Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347:1151–1160.
   PubMed Web of Science ®Google Scholar
• Novak N, Kruse S, Kraft S, et al. Dichotomic nature of atopic dermatitis reflected by combined analysis of monocyte immunophenotyping and single nucleotide polymorphisms of the interleukin-4/interleukin-13 receptor gene: the dichotomy of extrinsic and intrinsic atopic dermatitis. J Invest Dermatol. 2002;119:870–875.
   PubMed Web of Science ®Google Scholar
• Demehri S, Morimoto M, Holtzman MJ, et al. Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. PLoS Biol. 2009;7:e1000067.
   PubMed Web of Science ®Google Scholar
• Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372:803–813.
   PubMed Web of Science ®Google Scholar
• Flohr C, Johansson SG, Wahlgren CF, et al. How atopic is atopic dermatitis? J Allergy Clin Immunol. 2004;114:150–158.
   PubMed Web of Science ®Google Scholar
• Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832–836.
   PubMed Web of Science ®Google Scholar
• Anderson YMF, Egeberg A, Gislason GH, et al. Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;138:310–312.e3.
   Google Scholar
• Silverberg JI. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies. Allergy. 2015;70:1300–1308.
   PubMed Web of Science ®Google Scholar
• Arana A, Wentworth CE, Fernández-Vidaurre C, et al. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the UK. Br J Dermatol. 2010;163:1036–1043.
   PubMed Web of Science ®Google Scholar
• Andersen YMF, Egeberg A, Skov L, et al. Comorbidities of atopic dermatitis: beyond rhinitis and asthma. Curr Derm Rep. 2017;6:35–41.
   PubMed Web of Science ®Google Scholar
• NHS. Providing care for patients with skin conditions: guidance and resources for commissioners. London: Department of Health; 2008. Available from: http://www.pcds.org.uk/images/stories/nhs-pcpsc.pdf.
   Google Scholar
• NICE. Atopic eczema in under 12s: diagnosis and management. Clinical guideline [CG57]. London: NICE; 2007. Available from: https://www.nice.org.uk/guidance/cg57.
   Google Scholar
• NICE. Treating eczema in people over 12. London: NICE; 2019. Available from: http://pathways.nice.org.uk/pathways/eczema
   Google Scholar
• Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol. 2006;118:152–169.
   PubMed Web of Science ®Google Scholar
• Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Ann Allergy Asthma Immunol. 2004;93(3 Suppl. 2):S1–S21.
   PubMed Web of Science ®Google Scholar
• Lucky AW, Leach AD, Laskarzewski P, et al. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol. 1997;14:321–324.
   PubMed Web of Science ®Google Scholar
• Giordano-Labadie F, Cambazard F, Guillet G, et al. Evaluation of a new moisturizer (Exomega milk) in children with atopic dermatitis. J Dermatolog Treat. 2006;17:78–81.
   PubMed Web of Science ®Google Scholar
• Holden C, English J, Hoare C, et al. Advised best practice for the use of emollients in eczema and other dry skin conditions. J Dermatolog Treat. 2002;13:103–106.
   PubMed Web of Science ®Google Scholar
• Danby SG, Brown K, Higgs-Bayliss T, et al. The effect of an emollient containing urea, ceramide NP, and lactate on skin barrier structure and function in older people with dry skin. Skin Pharmacol Physiol. 2016;29:135–147.
   PubMed Web of Science ®Google Scholar
• Grether-Beck S, Felsner I, Brenden H, et al. Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression. J Invest Dermatol. 2012;132:1561–1572.
   PubMed Web of Science ®Google Scholar
• Cork MJ, Timmins J, Holden C, et al. An audit of adverse drug reactions to aqueous cream in children with atopic eczema. Pharm J. 2003;271:746–747.
   Google Scholar
• Tsang M, Guy RH. Effect of aqueous cream BP on human stratum corneum in vivo. Br J Dermatol. 2010;163:954–958.
   PubMed Web of Science ®Google Scholar
• Danby SG, Al-Enezi T, Sultan A, et al. The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis. Br J Dermatol. 2011;165:329–334.
   PubMed Web of Science ®Google Scholar
• Lammintausta K, Maibach HI, Wilson D. Human cutaneous irritation: induced hyporeactivity. Contact Dermatitis. 1987;17:193–198.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134:818–823.
   PubMed Web of Science ®Google Scholar
• Åkerström U, Reitamo S, Langeland T, et al. Comparison of moisturizing creams for the prevention of atopic dermatitis relapse: a randomized double-blind controlled multicentre clinical trial. Acta Derm Venereol. 2015;95:587–592.
   PubMed Web of Science ®Google Scholar
• Batchelor JM, Ridd MJ, Clarke T, et al. The Eczema Priority Setting Partnership: a collaboration between patients, carers, clinicians and researchers to identify and prioritize important research questions for the treatment of eczema. Br J Dermatol. 2013;168:577–582.
   PubMed Web of Science ®Google Scholar
• Ellison JA, Patel L, Ray DW, et al. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics. 2000;105:794–799.
   PubMed Web of Science ®Google Scholar
• Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931–936.
   PubMed Web of Science ®Google Scholar
• Kojima R, Fujiwara T, Matsuda A, et al. Factors associated with steroid phobia in caregivers of children with atopic dermatitis. Pediatr Dermatol. 2013;30:29–35.
   PubMed Web of Science ®Google Scholar
• Hon KL, Kam WY, Leung TF, et al. Steroid fears in children with eczema. Acta Paediatr. 2006;95:1451–1455.
   PubMed Web of Science ®Google Scholar
• Moret L, Anthoine E, Aubert-Wastiaux H, et al. TOPICOP©: a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents. PLoS One. 2013; 8:e76493.
   PubMed Web of Science ®Google Scholar
• Ellis C, Luger T, Abeck D, et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol. 2003;148(Suppl. 63):3–10.
   PubMed Web of Science ®Google Scholar
• du Vivier A. Tachyphylaxis to topically applied steroids. Arch Dermatol. 1976;112:1245–1248.
   PubMed Web of Science ®Google Scholar
• Danby SG, Chittock J, Brown K, et al. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. Br J Dermatol. 2014;170:914–921.
   PubMed Web of Science ®Google Scholar
• Ibbotson SH, Bilsland D, Cox NH, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol. 2004;151:283–297.
   PubMed Web of Science ®Google Scholar
• Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med. 1997;336:1041–1045.
   PubMed Web of Science ®Google Scholar
• Lee E, Koo J, Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol. 2005;44:355–360.
   PubMed Web of Science ®Google Scholar
• Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Derm Venereol. 2012;26:22–31.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77:623–633.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327–349.
   PubMed Web of Science ®Google Scholar
• Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367:839–846.
   PubMed Web of Science ®Google Scholar
• Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 1991;338:137–140.
   PubMed Web of Science ®Google Scholar
• Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128:353–359.
   PubMed Web of Science ®Google Scholar
• Fuggle NR, Bragoli W, Mahto A, et al. The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring. J Am Acad Dermatol. 2015;72:108–114.
   PubMed Web of Science ®Google Scholar
• Baron ED, Barzilai D, Johnston G, et al. Atopic dermatitis management: comparing the treatment patterns of dermatologists in Japan, USA and UK. Br J Dermatol. 2002;147:710–715.
   PubMed Web of Science ®Google Scholar
• Proudfoot LE, Powell AM, Ayis S, et al. The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey. Br J Dermatol. 2013;169:901–909.
   PubMed Web of Science ®Google Scholar
• Dupixent® (dupilumab) injection: Highlights of prescribing information. Tarrytown, NY/Bridgewater, NJ: Regeneron Pharmaceuticals, Inc./Sanofi-Aventis US LLC; 2019 [cited 2019 Sept]. Available from: https://www.regeneron.com/sites/default/files/Dupixent_FPI.pdf
   Google Scholar
• Dupixent® (dupilumab) summary of product characteristics. Brussels: European Commission; 2019. Available from: https://ec.europa.eu/health/documents/community-register/2019/20190801145601/anx_145601_en.pdf.
   Google Scholar